Immune Pharmaceuticals to present at Sachs Immuno-Oncology Business Development (BD&L) and Investment Forum in Chicago and at Marcum Conference in New York
May 27, 2015
NEW YORK, May 27, 2015 /PRNewswire/ -- Immune Pharmaceuticals ("Immune" or the "Company") (NASDAQ: IMNP) will present at the following two conferences this week:
Marcum Microcap Conference, May 28, 2015, at 1:30 p.m. EDT in the Uris Room at the Grand Hyatt New York.
Sachs Immuno-Oncology BD&L and Investment Forum in Chicago, May 29, 2015, at 2:10 pm CDT in Room B at the Hyatt Chicago Magnificent Mile.
At the Marcum Conference, Dr. Daniel Teper, CEO of Immune, will provide a strategic, financial and operational update for investors.
During the Sachs Immuno-Oncology BD&L and Investment Forum, Dr. Teper will discuss the development and partnering strategy for NanomAbs, its antibody nanoparticle conjugate platform for the targeted delivery of chemotherapeutics. Immune recently announced a partnership with STC Biologics for the development of anti-HER2 paclitaxel NanomAbs as well as other development candidates leveraging additional chemotherapeutics and monoclonal antibodies.
Both presentations will be available at www.immunepharmaceuticals.com.
On May 26, 2015, Immune celebrated its new global headquarters at the Alexandria Center for Life Science in New York City and the company's listing on NASDAQ with the ringing of the closing bell of the exchange.
About Immune Pharmaceuticals Inc.
Immune Pharmaceuticals Inc. applies a personalized approach to treatment, developing novel, highly-targeted antibody therapeutics to improve the lives of patients with inflammatory diseases and cancer. The Company's lead product candidate, bertilimumab, is in clinical development for moderate to severe ulcerative colitis and Crohn's disease as well as bullous pemphigoid, an orphan auto-immune dermatological condition. Immune licensed worldwide rights for systemic indications of bertilimumab from iCo Therapeutics (TSX: ICO; OTCQX: ICOTF) in June 2011, while iCo retained rights to all ophthalmic indications. iCo originally licensed the exclusive world-wide rights to bertilimumab in 2006 from MedImmune, the Global Research and Development arm of AstraZeneca. Immune's pipeline also includes NanomAbs, antibody nanoparticle conjugates, for the targeted delivery of chemotherapeutics, and AmiKet, a Neuropathic Pain drug candidate ready for Phase III. AmiKet has received Orphan Drug Designation for Post Herpetic Neuralgia.
For more information, visit Immune's website at www.immunepharmaceuticals.com, the content of which is not a part of this press release.
About STC Biologics
STC Biologics, Inc. is a biotechnology company with laboratories in Cambridge, MA USA focusing on development of biologics and complex products. STC's drug portfolio includes a diversified mix of biosimilars and novel biologics. STC's bioservices group caters to wider product classes, including peptides, RNA and liposomal products, in addition to complex glycoproteins and biosimilars. STC's core competency is in generating biologic drugs with specific product attributes through innovations in process development and understanding structure-activity-relationships. STC's team has brought several biologics to global regulatory approvals, with more than fifty years of collective experience in drug development.
This news release and any oral statements made with respect to the information contained in this news release contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. You are urged to consider statements that include the words "may," "will," "would," "could," "should," "believes," "estimates," "projects," "potential," "expects," "plans," "anticipates," "intends," "continues," "forecast," "designed," "goal" or the negative of those words or other comparable words to be uncertain and forward-looking. Such forward-looking statements include statements that express plans, anticipation, intent, contingency, goals, targets, future development and are otherwise not statements of historical fact. These statements are based on our current expectations and are subject to risks and uncertainties that could cause actual results or developments to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. Factors that may cause actual results or developments to differ materially include, but not limited to: the risks associated with the adequacy of our existing cash resources and our ability to continue as a going concern; the risks associated with our ability to continue to meet our obligations under our existing debt agreements; the risk that clinical trials for bertilimumab or AmiKet will not be successful; the risk that bertilimumab, AmiKet or compounds arising from our NanomAb program will not receive regulatory approval or achieve significant commercial success; the risk that we will not be able to find a partner for AmiKet on attractive terms, on a timely basis or at all; the risk that our other product candidates that appeared promising in early research and clinical trials do not demonstrate safety and/or efficacy in larger-scale or later-stage clinical trials; the risk that we will not obtain approval to market any of our product candidates; the risks associated with dependence upon key personnel; the risks associated with reliance on collaborative partners and others for further clinical trials, development, manufacturing and commercialization of our product candidates; the cost, delays and uncertainties associated with our scientific research, product development, clinical trials and regulatory approval process; our history of operating losses since our inception; the highly competitive nature of our business; risks associated with litigation; and risks associated with our ability to protect our intellectual property. These factors and other material risks are more fully discussed in our periodic reports, including our reports on Forms 8-K, 10-Q and 10-K and other filings with the U.S. Securities and Exchange Commission. You are urged to carefully review and consider the disclosures found in our filings which are available at www.sec.gov or at www.immunepharmaceuticals.com. You are cautioned not to place undue reliance on any forward-looking statements, any of which could turn out to be wrong due to inaccurate assumptions, unknown risks or uncertainties or other risk factors. We expressly disclaim any obligation to publicly update any forward looking statements contained herein, whether as a result of new information, future events or otherwise, except as required by law.
SOURCE Immune Pharmaceuticals Inc.
For further information: Immune Pharmaceuticals Inc., Anna Baran, Director, Corporate Affairs, Tel: 646 561-8010, firstname.lastname@example.org